Analysts Set OptimizeRx Corp. (NASDAQ:OPRX) PT at $11.43

OptimizeRx Corp. (NASDAQ:OPRX – Get Free Report) has received an average rating of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $11.4286.

A number of equities analysts have commented on the stock. UBS Group set a $11.00 price objective on shares of OptimizeRx in a research note on Friday, August 14th. Citizens Jmp increased their price target on shares of OptimizeRx from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Friday, August 14th. Weiss Ratings raised shares of OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, August 25th. Citigroup reiterated a “market outperform” rating on shares of OptimizeRx in a research report on Friday, August 14th. Finally, Wall Street Zen cut OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th.

Get OptimizeRx alerts:

View Our Latest Stock Report on OPRX

Hedge Funds Weigh In On OptimizeRx

Large investors have recently modified their holdings of the stock. Next Century Growth Investors LLC grew its holdings in OptimizeRx by 139.8% during the 4th quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company’s stock valued at $6,196,000 after purchasing an additional 294,688 shares during the last quarter. AWM Investment Company Inc. bought a new stake in OptimizeRx in the second quarter worth about $1,375,000. Segall Bryant & Hamill LLC bought a new stake in OptimizeRx in the first quarter worth about $1,185,000. Renaissance Technologies LLC boosted its position in shares of OptimizeRx by 633.2% during the first quarter. Renaissance Technologies LLC now owns 216,856 shares of the company’s stock valued at $1,362,000 after buying an additional 187,278 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of OptimizeRx by 22.3% during the first quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock valued at $3,540,000 after buying an additional 102,661 shares during the period. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Stock Performance

NASDAQ:OPRX opened at $7.62 on Friday. The company has a market cap of $143.56 million, a price-to-earnings ratio of 33.13 and a beta of 1.09. OptimizeRx has a 1 year low of $4.54 and a 1 year high of $22.25. The stock’s 50 day simple moving average is $7.30 and its two-hundred day simple moving average is $6.43. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.58 and a quick ratio of 5.58.

OptimizeRx (NASDAQ:OPRX – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. OptimizeRx had a return on equity of 9.44% and a net margin of 4.66%.The firm had revenue of $20.50 million during the quarter, compared to the consensus estimate of $20.20 million. As a group, equities analysts anticipate that OptimizeRx will post 0.51 earnings per share for the current fiscal year.

About OptimizeRx

(Get Free Report)

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health company that provides technology and data-driven engagement solutions for life sciences companies, healthcare providers and patients. Its platform is designed to support communication across the healthcare journey, helping pharmaceutical and biotechnology companies connect with clinicians and patients through digital channels.

The company’s solutions include point-of-care messaging, patient savings and financial assistance programs, medication adherence and support services, and analytics and audience-engagement tools.

Featured Stories

• Five stocks we like better than OptimizeRx
• Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
• Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
• AMD Chips Away at NVIDIA’s AI Throne
• Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.